Australia markets close in 1 hour 45 minutes

23andMe Holding Co. (ME)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.5233-0.0067 (-1.26%)
At close: 04:00PM EDT
0.5199 -0.00 (-0.65%)
After hours: 07:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.5300
Open0.5310
Bid0.5150 x 800
Ask0.5243 x 400
Day's range0.4940 - 0.5390
52-week range0.3500 - 2.1500
Volume3,737,897
Avg. volume5,896,719
Market cap255.946M
Beta (5Y monthly)1.24
PE ratio (TTM)N/A
EPS (TTM)-1.1000
Earnings date23 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est1.23
  • GlobeNewswire

    Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals

    Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activitySUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.’s (Nasdaq: PTPI), prescription erectile dysfunction (ED) medication STENDRAⓇ (avanafil) through its telehealth platform. Working direct

  • Bloomberg

    Struggling 23andMe Granted Extension to Revive Stock Price

    (Bloomberg) -- Embattled DNA-testing firm 23andMe Holding Co. has been granted an additional 180 days to move its shares above $1 and avoid being delisted, according to a filing with the Securities and Exchange Commission.Most Read from BloombergPutin Appoints Economist as Defense Minister in Shock ReshuffleTrump Vows ‘Day One’ Executive Order Targeting Offshore WindHow One Brooklyn Neighborhood Became a Nightclub HavenTrump Pledges Across-the-Board Tax Cuts If He Returns to OfficeThe stock has

  • GlobeNewswire

    23andMe to Report Q4 and Full Year FY2024 Financial Results

    SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fourth quarter and full fiscal year 2024 (FY2024) after the market closes on Thursday, May 23, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discus